SEC Form 4 · accession 0001654954-17-003027

Cellular Biomedicine Group, Inc. · CBMG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Jan 21, 2017

Accepted (ET)

Apr 3, 2017 · 7:36 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001378624

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 27, 2017	A	120,000	$0.00	A	120,000	D
Common Stock^F2	Mar 27, 2017	F	975	$11.40	D	119,025	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy) (2011 Plan)^F3	$12.55	Jan 21, 2017	A	30,000	A	Jan 27, 2017	Jan 21, 2027	Common Stock	30,000	30,000	D
Non-Qualified Stock Option (right to buy) (2014 Plan)^F4	$12.40	Mar 3, 2017	A	120,000	A	—	Mar 3, 2027	Common Stock	120,000	120,000	D

F1The Reporting Person was granted 120,000 restricted stock units ("RSUs") (Grant No. LTIP RSU G1) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan, which RSUs vest according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
F2On March 27, 2017, 2,500 RSUs (Grant No. LTIP RSU G1 ) vested and were delivered to the Reporting Person, of which 975 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Tuesday, March 27, 2017) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Securities Exchange Act of 1934.
F3This option (Grant No. 11-273) vested immediately on January 21, 2017.
F4This option (Grant No. 14-324) vests over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.